Work

Abstract CT262: Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct262

Authors: Hearn J. Cho, Shambavi Richard, Alex Lesokhin, Noa Biran, Barry Paul, Ravi Vij, Matthew Pianko, Deon Doxie, Mercedes Martillo, Katie Wozniak, Kavita Dhodapkar, Madhav Dhodapkar

Institutions: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Levine Cancer Institute, Washington University in St. Louis, University of Michigan, U-M Rogel Cancer Center, Emory University, Winship Cancer Institute, Multiple Myeloma Research Foundation

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365512354

Cites:

Cited by: 4

Related to: 10